Navigation Links
Ethicon Endo-Surgery to Acquire SurgRx
Date:8/11/2008

- Acquisition will bring together two complementary technologies to extend reach into multiple key surgical activities, offering improved options for

physicians and patients worldwide -

CINCINNATI, Aug. 11 /PRNewswire/ -- Ethicon Endo-Surgery announced today that it has entered into a definitive agreement to acquire SurgRx, a privately held developer of the advanced bipolar tissue sealing system used in the EnSeal(R) family of devices. The acquisition will provide Ethicon Endo-Surgery with a new energy platform, which complements its HARMONIC(R) line of ultrasonic medical devices that have been used to perform open and laparoscopic procedures worldwide.

Terms of the agreement were not disclosed. The transaction is subject to customary clearances, including the Hart-Scott-Rodino Antitrust Improvements Act and similar regulations in other countries.

"Ethicon Endo-Surgery and SurgRx share a commitment to innovation for the surgeons and patients who depend on our products," said Karen Licitra, Company Group Chairman and Worldwide Franchise Chairman, Ethicon Endo-Surgery. "Together, the combination of HARMONIC(R) and EnSeal(R) technologies will position us to better address many different procedure needs."

"The acquisition has the potential to expand the global availability of the EnSeal(R) product line," said Rodney Perkins M.D., Chairman, Board of Directors, SurgRx. Dave Clapper, President & CEO, SurgRx added, "We are looking forward to joining forces with Ethicon Endo-Surgery to offer these complementary technologies to even more patients worldwide." SurgRx was founded in 2002 and is located in Redwood City, Calif. The EnSeal(R) family of devices combines high compression and controlled energy delivery to quickly create strong vessel seals. The EnSeal(R) device, cleared by the FDA in 2003, is capable of sealing vessels up to 7mm in diameter.

About Ethicon Endo-Surgery

Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at http://www.ethiconendo.com.

HARMONIC is a trademark of Ethicon Endo-Surgery, Inc.

EnSeal is a trademark of SurgRx, Inc.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Ethicon Endo-Surgery's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including receipt of regulatory approvals for the transaction, and the possibility that the transaction will not be completed; general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Ethicon Endo-Surgery does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Ethicon Endo-Surgery, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
2. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
3. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
4. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
7. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
8. Teva to Acquire Barr
9. MacroGenics Acquires Raven Biotechnologies
10. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
11. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):